147 related articles for article (PubMed ID: 8804062)
1. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function.
Van Eyll B; Göke B; Wilmen A; Göke R
Peptides; 1996; 17(4):565-70. PubMed ID: 8804062
[TBL] [Abstract][Full Text] [Related]
2. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
Heller RS; Kieffer TJ; Habener JF
Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
[TBL] [Abstract][Full Text] [Related]
3. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
4. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1.
Wilmen A; Van Eyll B; Göke B; Göke R
Peptides; 1997; 18(2):301-5. PubMed ID: 9149304
[TBL] [Abstract][Full Text] [Related]
5. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity.
Wilmen A; Göke B; Göke R
FEBS Lett; 1996 Nov; 398(1):43-7. PubMed ID: 8946950
[TBL] [Abstract][Full Text] [Related]
6. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
7. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
8. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
9. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate.
Widmann C; Dolci W; Thorens B
Mol Endocrinol; 1996 Jan; 10(1):62-75. PubMed ID: 8838146
[TBL] [Abstract][Full Text] [Related]
10. The human glucagon-like peptide-1 (GLP-1) receptor. Cloning and functional expression.
Dillon JS; Wheeler MB; Leng XH; Ligon BB; Boyd AE
Adv Exp Med Biol; 1997; 426():113-9. PubMed ID: 9544263
[No Abstract] [Full Text] [Related]
11. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
12. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
13. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
Underwood CR; Garibay P; Knudsen LB; Hastrup S; Peters GH; Rudolph R; Reedtz-Runge S
J Biol Chem; 2010 Jan; 285(1):723-30. PubMed ID: 19861722
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.
Yang H; Egan JM; Wang Y; Moyes CD; Roth J; Montrose MH; Montrose-Rafizadeh C
Am J Physiol; 1998 Sep; 275(3):C675-83. PubMed ID: 9730951
[TBL] [Abstract][Full Text] [Related]
16. Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding.
Unson CG; Cypess AM; Kim HN; Goldsmith PK; Carruthers CJ; Merrifield RB; Sakmar TP
J Biol Chem; 1995 Nov; 270(46):27720-7. PubMed ID: 7499239
[TBL] [Abstract][Full Text] [Related]
17. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Al-Sabah S; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):9-14. PubMed ID: 14965273
[TBL] [Abstract][Full Text] [Related]
18. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
[TBL] [Abstract][Full Text] [Related]
19. The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists.
Al-Sabah S; Donnelly D
FEBS Lett; 2003 Oct; 553(3):342-6. PubMed ID: 14572647
[TBL] [Abstract][Full Text] [Related]
20. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge.
López de Maturana R; Donnelly D
FEBS Lett; 2002 Oct; 530(1-3):244-8. PubMed ID: 12387900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
